|
nasopharyngeal carcinoma |
16 |
|
survival |
14 |
|
hepatocellular carcinoma |
13 |
|
radiotherapy |
10 |
|
targeted therapy |
10 |
|
non-small cell lung cancer |
9 |
|
bintrafusp alfa |
8 |
|
chemotherapy |
8 |
|
correlative biomarkers |
8 |
|
efficacy |
8 |
|
nomogram |
8 |
|
outcomes |
8 |
|
recurrent or metastatic nasopharyngeal cancer |
8 |
|
safety |
8 |
|
stereotactic body radiation therapy |
8 |
|
transarterial chemoembolization |
8 |
|
unresectable |
8 |
|
colorectal cancer |
6 |
|
decision-making |
6 |
|
economic evaluation |
6 |
|
economic evidence |
6 |
|
simulation models |
6 |
|
hcc |
5 |
|
intensity-modulated radiotherapy |
5 |
|
local recurrence |
5 |
|
radiosurgery |
5 |
|
reirradiation |
5 |
|
re‐irradiation |
5 |
|
salvage |
5 |
|
second primary cancer |
5 |
|
surgery |
5 |
|
survivorship |
5 |
|
toxicities |
5 |
|
adaptive planning |
4 |
|
adult oncology |
4 |
|
ajcc/uicc staging system |
4 |
|
checkpoint inhibitor |
4 |
|
epidemiology |
4 |
|
high dose rate endorectal brachytherapy |
4 |
|
igrt |
4 |
|
immunotherapy |
4 |
|
impt |
4 |
|
imrt |
4 |
|
liver transplantation |
4 |
|
medically inoperable |
4 |
|
metastatic colorectal cancer |
4 |
|
palliative care |
4 |
|
prognostic factors |
4 |
|
rectal brachytherapy |
4 |
|
rectal cancer |
4 |
|
recurrence |
4 |
|
refractory |
4 |
|
regorafenib |
4 |
|
statistics & research methods |
4 |
|
stereotactic ablative radiation therapy |
4 |
|
stereotactic radiation therapy |
4 |
|
systematic review |
4 |
|
tmn classification |
4 |
|
toxicity |
4 |
|
trifluridine/tipiracil (tas-102) |
4 |
|
atezolizumab plus bevacizumab |
3 |
|
bridging therapy |
3 |
|
cost-effective analysis |
3 |
|
magnetic resonance imaging |
3 |
|
transarterial chemoembolisation |
3 |
|
transarterial radioembolisation |
3 |
|
adverse events |
2 |
|
antineoplastic drugs |
2 |
|
chemoradiotherapy |
2 |
|
palbi |
2 |
|
pancreatic neoplasms |
2 |
|
radiomics |
2 |
|
rectal neoplasms |
2 |
|
stereotactic body radiotherapy |
2 |
|
survival prediction |
2 |
|
trans-arterial chemoembolization |
2 |
|
adult |
1 |
|
advanced cancer patients |
1 |
|
antisense oligonucleotides |
1 |
|
bclc stage b-c |
1 |
|
breathing |
1 |
|
controlled study |
1 |
|
ct-guided brachy |
1 |
|
dose delivery quality assurance |
1 |
|
edmonton symptom assessment scale |
1 |
|
equivalent uniform dose |
1 |
|
esas |
1 |
|
four dimensional computed tomography |
1 |
|
friedman test |
1 |
|
hdr |
1 |
|
hepatocellular carcinoma (hcc) |
1 |
|
high-dose-rate |
1 |
|
initial therapy |
1 |
|
internal radiation therapy |
1 |
|
karnofsky performance scale |
1 |
|
kps |
1 |
|
linear-quadratic model |
1 |
|
liver cancer |
1 |
|
lung cancer |
1 |
|
lung cancers |
1 |
|
margins of excision |
1 |
|
measurement-guided dose reconstruction |
1 |
|
planning target margin |
1 |
|
primary liver cancer |
1 |
|
qausi-3d dosimetry |
1 |
|
randomized phase ii trial |
1 |
|
tumor |
1 |
|
universal survival curve |
1 |
|
x-linked inhibitor of apoptosis protein (xiap) |
1 |
